Solaini Leonardo, Ministrini Silvia, Tomasoni Matteo, Merigo Giulia, Gaverini Giacomo, Bertoloni Giam Paolo, Tiberio Guido A M
Department of Medical and Surgical Sciences, Surgical Clinic, University of Brescia, Pl.e Spedali Civili 1, Brescia, Italy,
Endocrine. 2015 Sep;50(1):187-92. doi: 10.1007/s12020-015-0596-8. Epub 2015 Apr 12.
The purpose of this study was to analyze our experience with surgically treated isolated adrenal metastases in order to find those factors which can significantly affect survival. This method includes a retrospective single-center chart review. We evaluated how overall survival and disease-free survival (DFS) were influenced by demographic, tumor, and procedure-related variables. Thirty-seven adrenalectomies were performed in 34 patients. Procedures included 25 laparoscopic and 12 open adrenalectomies. Median follow-up was 49 months. Median overall survival was 63 months. Patients submitted to laparoscopic approach had a median survival of 57 months while it was 65 months for those who underwent open procedure (p = 0.67). DFS was 30 months, and these were 35 and 25 months after laparoscopic approach and open approach, respectively (p = 0.59). The concurrent resection of the adrenal metastasis with the primary tumor was the only factor influencing DFS (HR 6.8 95 % CI 1.2-37.3, p = 0.02). Patients with non-small cell lung cancer (n = 15) had a median survival of 63 months and DFS of 35 months. Our experience confirms that adrenalectomy, regardless of the surgical approach, can offer durable disease-free and overall survival outcomes for surgical candidates with isolated adrenal metastases.
本研究的目的是分析我们手术治疗孤立性肾上腺转移瘤的经验,以找出那些能显著影响生存的因素。该方法包括回顾性单中心病历审查。我们评估了总体生存和无病生存(DFS)如何受到人口统计学、肿瘤及手术相关变量的影响。34例患者接受了37次肾上腺切除术。手术方式包括25例腹腔镜肾上腺切除术和12例开放性肾上腺切除术。中位随访时间为49个月。中位总生存期为63个月。接受腹腔镜手术的患者中位生存期为57个月,而接受开放手术的患者为65个月(p = 0.67)。DFS为30个月,腹腔镜手术和开放手术后分别为35个月和25个月(p = 0.59)。肾上腺转移瘤与原发肿瘤同期切除是影响DFS的唯一因素(HR 6.8,95%CI 1.2 - 37.3,p = 0.02)。非小细胞肺癌患者(n = 15)的中位生存期为63个月,DFS为35个月。我们的经验证实,无论采用何种手术方式,肾上腺切除术都能为有孤立性肾上腺转移瘤的手术候选者提供持久的无病生存和总体生存结果。